Loading
A Chinese case-control study developing a blood test for five common cancers from DNA methylation, DNA fragments and proteins.
PROFUTURE (NCT05874648) is an observational study sponsored by Sixth Affiliated Hospital, Sun Yat-sen University with Shanghai Weihe Medical Laboratory Co., Ltd. It collects blood to develop machine-learning models that combine cell-free DNA methylation, fragmentation and proteomics.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 25 May 2023), with an estimated 3,830 participants, a planned start in 7 July 2023 and primary completion expected on 30 April 2024.
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/